Atara Biotherapeutics
ATRA
32 hedge funds and large institutions have $13.9M invested in Atara Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 9 closing their positions.
12% more capital invested
Capital invested by funds: $12.4M → $13.9M (+$1.53M)
5.36% less ownership
Funds ownership: 35.61% → 30.25% (-5.4%)
14% less funds holding
Funds holding: 37 → 32 (-5)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$309K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$168K |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$164K |
| 4 |
BlackRock
New York
|
+$73.3K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$29.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.31M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$447K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$365K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$244K |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
-$131K |
ATRA Hedge Fund Activity: Q2 2025 in Review
32 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2025, worth a combined $13.9M — up 12% from $12.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ATRA and 4 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $309K. The largest seller was Bank of America, cutting an estimated $1.31M.
- 32 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2025, down from 37 in Q1 2025.
- Funds reported $13.9M of Atara Biotherapeutics stock for Q2 2025, up 12% quarter-over-quarter.
- 4 funds opened new Atara Biotherapeutics positions in Q2 2025 and 9 closed out, a net change of -5 holders.
- The largest Atara Biotherapeutics buyer in Q2 2025 was Marshall Wace, an estimated $309K added.
- The largest Atara Biotherapeutics seller in Q2 2025 was Bank of America, an estimated $1.31M sold.
Based on aggregated 13F filings for Q2 2025.